Slide 1: Investor Relations
Investor Relations April 28, 2022
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2022 guidance, 2025 targets, growth targets, other expectations and other non-historical information.
Slide 3: Vision: The Autonomous Pharmacy
VISION The Autonomous Pharmacy will transform the pharmacy care delivery model by enabling the provider to practice at the top of their license. © 2022 Omnicell, Inc. 3
Slide 4: Delivering Strong Results and Building Momentum
Delivering Strong Results and Building Momentum Projected Long-Term Value Upside FY 2021 Actuals Clear leadership position in the digital transformation of healthcare with $70B+ Total Addressable Market (TAM) $1.217B $1.133B $230M $3.81 Product Bookings Total Non-GAAP Revenue Non-GAAP EBITDA Non-GAA
Slide 5: Well-Positioned for Continued Growth and Shareholder Value Creation
Well-Positioned for Continued Growth and Shareholder Value Creation 1 2 3 4 Category creator Leading strategic partner Resilient, high-visibility Demonstrated track positioned to transform to health systems in large revenue accelerated by record of growth and the pharmacy care and growing market hig
Slide 6: Solutions for an Expensive and Error-Prone Medication Management Reality
1 Omnicell Provides Solutions for an Expensive and Error-Prone Medication Management Reality Medication Management is Expensive and Error-Prone Omnicell's Current Solutions Deliver Results6 25,000 4 47 million 1 Enhanced 99.999997% Safety Errors Annually Errors Per Day in Doses Lost to Error Per 200
Slide 7: Autonomous Pharmacy Framework
1 Autonomous Pharmacy Framework Increasing healthcare value In 2019, leading health systems jointly created a framework analyzing the technological maturity of pharmacies The group determined there was a significant opportunity to drive greater healthcare value The group established a 5-level framew
Slide 8: Omnicell's Autonomous Pharmacy: A New Category of Solutions
1 Omnicell’s Autonomous Pharmacy is a New Category of Solutions That Fundamentally Improves Provider Outcomes Omnicell One™ CPDS IVCS EnlivenHealth® Omnicell340B ReCept Future Services1 One Platform Omnicell Future Devices1 Connected Devices XT Automated Anesthesia XR2 Robot IV Robot IVX Workflow Di
Slide 9: Leader in Large and Growing Segments
2 Leader in Large and Growing Segments Omnicell is growing its leadership position across a $70B+ TAM Estimated TAM Opportunity1 Key Advanced Services Point of Care $20B Omnicell One™ CPDS Central Pharmacy $15B Omnicell 340B IVCS 340B Software – Enabled Services $12B Retail, Institutional and Payers
Slide 10: Resilient and High-Visibility Revenue
3 Resilient and High-Visibility Revenue Connected Devices, Software Licenses & Other3 Recurring Technical Services and Other Recurring5 Recurring SaaS, Subscription Software & Tech-Enabled Services4 Robust Robust product backlog Backlog ~25% Types of ~10% Deep 151 of the top 300 U.S. health Customer
Slide 11: Advanced Services Accelerating Recurring Revenue Growth
3 Advanced Services Accelerating Recurring Revenue Growth Leveraging established channel SaaS, Subscription Software & Tech-Enabled and strong customer relationships Services (% of Total Revenue) 20-30% Strong demand driven by increasing provider digitization and need to evolve Targeting 14%-15% med
Slide 12: Driving Profitable Growth Through Disciplined Execution
4 Driving Profitable Growth Through Disciplined Execution Expected Annual Revenue ($ in Millions) $1,900-$2,000 $1,650- $1,750 Execute value-enhancing M&A $1,133 Drive innovation and continue to deliver the Autonomous Pharmacy Vision Continue market share gains Capitalize on upgrade cycles Continue
Slide 13: Continuing to Drive Margin Expansion
4 Continuing to Drive Margin Expansion Key Drivers of Margin Enhancement2 Improving Business Mix – SaaS, Subscription Targeted Non-GAAP Operating Margin (%) Software & Tech-Enabled Services targeted to represent 20-30% of revenue by 2025, supporting ~21% strong gross margins 16.3% Long-Term Customer
Slide 14: Well-Positioned for Continued Growth and Shareholder Value Creation
Well-Positioned for Continued Growth and Shareholder Value Creation 1 Category creator positioned to transform the pharmacy care delivery model Large portion of the healthcare sector: $1,331B annually globally 2 Leading strategic partner to health systems in large and growing market segments Clear l
Slide 15: Financial Guidance
Financial Guidance Includes the anticipated contributions and integration costs of recent acquisitions, as well as the anticipated effects of the current inflationary environment. Q2 2022 FY 2022 Product Bookings Not Provided $1.370 - 1.430 Billion Total GAAP and Non-GAAP Revenues $337 - 343 Million
Slide 16: Appendix
YEARS Appendix
Slide 17: Omnicell Delivers a Suite of Innovative Solutions
Omnicell Delivers a Suite of Innovative Solutions Service Technical Services Professional Services Advisory Services Outcomes Outcomes Omnicell One™ Safety + Intelligence Omnicell 340B 340B Analysis Inventory Analytics Diversion Management Compliance EnlivenHealth™ Financial Savings Operational + Su
Slide 18: Winning Go-To-Market Strategy
Winning Go-To-Market Strategy Long-term strategic partnerships with key customers Over half of the Top 300 U.S. Health Systems1 are current Omnicell customers 151 of those have entered into long-term sole source partnership agreements with Omnicell2 Multiyear co-development plans with the majority o
Slide 19: Multiyear Co-Development Plan Example: Large Health System Customer
Multiyear Co-Development Plan Example: Large Health System Customer Year 1 Year 2 Year 3 Year 4/5 KPI New Hospital Safety Efficiency Medical Center 1 Safety Efficiency University Campus People Compliance Medical Center 2 Safety Efficiency Medical Center 3 Safety Efficiency Medical Center 4 Financial
Slide 20: Omnicell's Strategic Approach to Corporate Responsibility
Environment Innovating for Energy Efficiency Integrate Omnicelts sustainable Procurement strategies across 700% of our Tier 1 High Risk suppliers by 2025. ‘Conduct a Scope 1 & 2 cimate Reduce scope 1 & 2 emissions by 25% by 2027 Establish Scope 3 reduction targets by 2030 network (customers) by 2025
Slide 21: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Year Ended December 2021 Reconciliation of GAAP revenues to non-GAAP revenues: GAAP revenues S$ 1132018 $ 892,208 Acquisiti ing impact related to 780 Non-GAAP revenues S128 7S 392208 Rec
Slide 22: Reconciliation of GAAP to Non-GAAP
‘Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) ‘Year Ended December 31, 2021 Reconciliation of GAAP net income to non-GAAP net income: GAAP net income s 77349 $ 32,194 Tax impact of IP restructuring (6202) . Share-based. 53,160 44,6
Slide 23: Reconciliation of GAAP Operating Cash Flow to Non-GAAP Free Cash Flow
(© 2022 Ompicell ne Reconciliation of GAAP net cash provided by operating activities to non-GAAP free cash flow: GAAP net cash provided by operating activities Software development for extemal use Purchases of property and equipment Non-GAAP free cash flow Year Ended December 31, 2021 2020 231,809 $
Slide 24: Years of Innovation
YEARS of INNOVATION